Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Purple Biotech (PPBT) Total Non-Current Liabilities (2016 - 2025)

Purple Biotech has reported Total Non-Current Liabilities over the past 7 years, most recently at $466000.0 for Q4 2022.

  • Quarterly Total Non-Current Liabilities fell 44.66% to $466000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $466000.0 through Dec 2022, down 44.66% year-over-year, with the annual reading at $466000.0 for FY2022, 44.66% down from the prior year.
  • Total Non-Current Liabilities was $466000.0 for Q4 2022 at Purple Biotech, down from $501000.0 in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $953000.0 in Q4 2020 and troughed at $254000.0 in Q2 2020.
  • The 5-year median for Total Non-Current Liabilities is $596000.0 (2022), against an average of $618214.3.
  • Year-over-year, Total Non-Current Liabilities plummeted 73.39% in 2018 and then soared 242.52% in 2021.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $405000.0 in 2018, then dropped by 22.72% to $313000.0 in 2019, then soared by 204.47% to $953000.0 in 2020, then dropped by 11.65% to $842000.0 in 2021, then tumbled by 44.66% to $466000.0 in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Total Non-Current Liabilities are $466000.0 (Q4 2022), $501000.0 (Q3 2022), and $691000.0 (Q2 2022).